- Conditions
- Pulmonary Hypertension
- Interventions
- Telaglenastat
- Drug
- Lead sponsor
- Chan, Stephen, MD, PhD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 887
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
- Interventions
- Balstilimab, Zalifrelimab, Doxorubicin, Botensilimab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Kidney Cancer
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Placebo, RO7204239
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Orange, California • Aurora, Colorado • Fairway, Kansas + 1 more
- Conditions
- Bladder Cancer, High Risk Superficial
- Interventions
- Bacillus Calmette-Guérin (BCG)
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
- Conditions
- Leukemia-Lymphoma, Adult T-Cell
- Interventions
- Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 6
- States / cities
- Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine, Placebo, Interferon-beta (IFN-beta)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 21
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
- Conditions
- Pancreas Neoplasm Malignant Resectable
- Interventions
- Folfox6, Gemcitabine, Radiation Therapy, Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
- Drug · Radiation · Procedure
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Obesity
- Interventions
- Angiotensin-(1-7), Saline
- Drug
- Lead sponsor
- Amy Arnold
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Nonmuscle-invasive Bladder Cancer
- Interventions
- T3011
- Biological
- Lead sponsor
- ImmVira Pharma Co. Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
- Conditions
- HIV-1 Infections
- Interventions
- dapivirine 4789, dapivirine gel 4759, Drug placebo
- Drug
- Lead sponsor
- International Partnership for Microbicides, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 22
- States / cities
- Concord, California • Encino, California • Escondido, California + 18 more
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma, Mantle Cell, Mantle Cell Lymphoma
- Interventions
- Rituximab (R), EPOCH, Bortezomib (B), Bortezomib, Bortezomib or observation
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- AZD6244 Dosing Period 1, AZD6244 Dosing Period 2, AZD6244 Dosing Period 3, AZD6244 Dosing Period 4
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Pembrolizumab, Ibrutinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 3,054 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 116
- States / cities
- Phoenix, Arizona • Downey, California • Duarte, California + 92 more
- Conditions
- Histiocytic Disorders
- Interventions
- Cobimetinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • New York, New York
- Conditions
- Trismus, Head and Neck Cancer
- Interventions
- Trismus Device Prototype, Questionnaires, Mobile Application
- Device · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Bladder Cancer
- Interventions
- Specimen Ultra-High field MRI, chemotherapy, Cystectomy and Lymphadenectomy
- Procedure · Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Colorectal Cancer
- Interventions
- Gene Modified T Cells
- Biological
- Lead sponsor
- Roger Williams Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Rheumatoid Arthritis
- Interventions
- Canakinumab
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 17 more
- Conditions
- Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Talazoparib, Atezolizumab, Radiation
- Drug · Radiation
- Lead sponsor
- Mylin A. Torres, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Atlanta, Georgia